Ovid Therapeutics Inc (OVID) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) has a cash flow conversion efficiency ratio of -0.080x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.41 Million) by net assets ($130.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Ovid Therapeutics Inc to measure how much of total assets are equity-financed.
Ovid Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Ovid Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ovid Therapeutics Inc (OVID) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Ovid Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ovid Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kernex Microsystems (India) Limited
NSE:KERNEX
|
-0.178x |
|
BOE Tech Group
SHE:200725
|
0.070x |
|
Websol Energy System Limited
NSE:WEBELSOLAR
|
0.338x |
|
S.C. CHIMCOMPLEX S.A.
RO:CRC
|
-0.008x |
|
D&O Home Collection Co Ltd
SHE:002798
|
0.039x |
|
China Merchants Port Group Co Ltd
SHE:201872
|
0.012x |
|
Banestes S.A - Banco do Estado do Espírito Santo
SA:BEES3
|
-1.747x |
|
General Oceans ASA
OL:GENO
|
0.033x |
Annual Cash Flow Conversion Efficiency for Ovid Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Ovid Therapeutics Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Ovid Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.66 Million | $-38.33 Million | -0.293x | +64.23% |
| 2024-12-31 | $68.23 Million | $-55.96 Million | -0.820x | -57.29% |
| 2023-12-31 | $87.80 Million | $-45.78 Million | -0.521x | -24.89% |
| 2022-12-31 | $132.27 Million | $-55.23 Million | -0.418x | -163.27% |
| 2021-12-31 | $179.75 Million | $118.61 Million | 0.660x | +155.82% |
| 2020-12-31 | $43.63 Million | $-51.58 Million | -1.182x | -62.04% |
| 2019-12-31 | $70.02 Million | $-51.09 Million | -0.730x | +37.85% |
| 2018-12-31 | $38.81 Million | $-45.56 Million | -1.174x | -211.27% |
| 2017-12-31 | $83.44 Million | $-31.47 Million | -0.377x | -4.44% |
| 2016-12-31 | $49.29 Million | $-17.80 Million | -0.361x | -348.12% |
| 2015-12-31 | $68.07 Million | $-5.49 Million | -0.081x | -46.14% |
| 2014-12-31 | $4.74 Million | $-261.28K | -0.055x | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human or… Read more